Global Pharmatech, Inc.
Global Pharmatech, Inc. (GBLP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gblp · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Global Pharmatech, Inc.You GBLP | $29M | 934.23x | — | $0.00 |
 Avicanna Inc. AVCNF | $10M | N/A | — | -$0.02 |
 INDVR Brands Inc. CAAOF | $0M | N/A | — | -$0.06 |
 Choom Holdings Inc. CHOOF | $0M | N/A | — | -$0.07 |
 Charlotte's Web Holdings, Inc. CWBHF | $67M | N/A | — | -$0.19 |
 Molecule Holdings Inc. EVRRF | $1M | N/A | — | -$0.05 |
 Isracann Biosciences Inc. ISCNF | $0M | N/A | — | -$0.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Global Pharmatech, Inc. (GBLP) measures how much investors pay for each dollar of the company's trailing earnings. GBLP's current PE ratio of 934.23x is calculated by dividing its stock price of $0.07 by its TTM earnings per share of $0.00.
Frequently asked questions
GBLP pe ratio · 6 questionsGBLP's current PE ratio is 934.23x as of 2026-06-09, based on a stock price of $0.07 and TTM EPS of $0.00. Data sourced from Financial Modeling Prep via GBLP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Global Pharmatech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09